se of serial 18F-fluorodeoxyglucose (FDG) and 18F-fluorothymidine (FLT) positron emission tomography (PET) & computed tomography (CT) for candidates with non-small cell lung cancer (NSCLC)receiving radical chemo-radiation therapy

Not Applicable

Recruiting

• Conditions: lung cancer; Cancer - Lung - Non small cell

• Registration Number: ACTRN12611001283965
• Lead Sponsor: Peter MacCallum Cancer Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-12-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Written informed consent provided.
Histologically or cytologically confirmed NSCLC.
Candidate for radical RT (60Gy) & concomitant chemotherapy (standard regimen determined by medical oncologist).
Stage I - III disease (TNM 7th edition).
ECOG performance status 0-1.

Exclusion Criteria

Received previous thoracic RT or a complete macroscopic excision of tumour.
Pregnancy (Women of child-bearing age to ensure adequate contraceptive measures).

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To simulate the administration of biologically adapted radiation therapy (BART) to patients with NSCLC using information gained from interim FLT & FDG PET/CT scans.[Following recruitment of all patients]

Secondary Outcome Measures

Name	Time	Method
To determine the role of interim FLT & FDG PET/CT scans as biomarkers of patient prognosis.[Overall survival (OS): time from first RT treatment until death from any cause.<br>Progression free survival (PFS): time from first RT until progression (local, regional & distant).<br>OS and PFS will be assessed clinically and with diagnostic imaging, including a follow-up FDG PET/CT scan.]